Hansoh Pharmaceutical Group Company Limited (HKG:3692)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 210.98B -3.3% |
| Revenue (ttm) | 18.35B +20.5% |
| Net Income | 7.71B +39.7% |
| EPS | 1.28 +37.9% |
| Shares Out | 6.06B |
| PE Ratio | 27.21 |
| Forward PE | 26.64 |
| Dividend | 0.43 (1.24%) |
| Ex-Dividend Date | Sep 22, 2026 |
| Volume | 9,744,869 |
| Open | 34.44 |
| Previous Close | 35.18 |
| Day's Range | 34.08 - 35.40 |
| 52-Week Range | 28.06 - 44.22 |
| Beta | 0.54 |
| Analysts | Strong Buy |
| Price Target | 48.61 (+39.68%) |
| Est. Earnings | Nov 26, 2026 |
About HKG:3692
Hansoh Pharmaceutical Group Company Limited, an investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China. The company provides products for therapeutic areas, including anti-infection, central nervous system, oncology, and metabolic and other diseases, as well as autoimmune diseases. Its principal products include Ameile, Hansoh Xinfu, Pulaile, Xintai, Xinmei, Gainuo, Tanneng, and Pulaitan; Hengmu, Hengsen, Oulanning, Ailanning, and Ameining; XINYUE; and ... [Read more]
Financial Performance
In 2025, HKG:3692's revenue was 15.03 billion, an increase of 22.57% compared to the previous year's 12.26 billion. Earnings were 5.56 billion, an increase of 27.07%.
Financial numbers in CNY Financial StatementsAnalyst Summary
According to 25 analysts, the average rating for 3692 stock is "Strong Buy." The 12-month stock price target is $48.61, which is an increase of 39.68% from the latest price.
News
GSK, Hansoh's bone cancer drug delays disease progression in late-stage China study
An experimental drug for a hard-to-treat bone cancer, being developed by Hansoh Pharmaceutical and GSK , helped patients live longer without the disease worsening, according to data presented by resea...
Hansoh Pharma Inks $15 Bln-Plus ADC Deal With Roche; Stock Up
(RTTNews) - Hansoh Pharmaceutical Group Co., Ltd. (HNSPF), a China-based pharmaceutical company, has entered into a strategic collaboration and licensing agreement with Roche Holding AG (RHHBY) to adv...
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion
China's Hansoh Pharmaceutical said on Monday its units have entered into a collaboration and licensing deal with Roche potentially worth more than $15 billion, covering a portfolio of antibody-drug co...
Hansoh Pharma reports 36% rise in first-half profit helped by innovative drug sales
China's Hansoh Pharmaceutical Group , a Roche partner, reported a near 36% rise in first-half profit on Wednesday, driven by strong growth in sales of innovative medicines and higher investment inco...
Hansoh Pharmaceutical Group Company Earnings release: H1 2026
Hansoh Pharmaceutical Group Company released its H1 2026 earnings on August 26, 2026, summarizing the period's financial results.
Hansoh Pharmaceutical Group Company Quarterly report: H1 2026
Hansoh Pharmaceutical Group Company has published its H1 2026 quarterly earnings report on August 26, 2026.
China's Hansoh Pharmaceutical Group beats net profit expectations in 2025
China's Hansoh Pharmaceutical Group , a Roche partner, reported a 27% rise in annual profit on Sunday, beating market expectations and boosted by income from innovative medicines and business develo...
Hansoh Pharmaceutical Group Company Earnings release: H2 2025
Hansoh Pharmaceutical Group Company released its H2 2025 earnings on March 28, 2026, summarizing the period's financial results.
Hansoh Pharmaceutical Group Company Annual report: H2 2025
Hansoh Pharmaceutical Group Company has published its H2 2025 annual report on March 28, 2026.